Table 4.
Associations between RNASEL and HPCX variants and Gleason score †
| Controls | Cases with Gleason 2–6 tumors | Cases with Gleason 7–10 tumors | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| RNASEL | n | % | n | % | OR‡ | 95% CI | n | % | OR‡ | 95% CI |
|
| ||||||||||
| 471delAAAG | ||||||||||
|
|
||||||||||
| No | 1212 | 98.0 | 522 | 98.5 | 1.00 | - | 333 | 90.7 | 1.00 | - |
| Yes | 25 | 2.0 | 8 | 1.5 | 0.75 | 0.33 – 1.68 | 9 | 2.5 | 1.31 | 0.60 – 2.86 |
|
| ||||||||||
| rs486907 (Arg462Gln) | ||||||||||
| GG | 572 | 46.2 | 271 | 50.4 | 1.00 | - | 154 | 43.6 | 1.00 | - |
| GA | 556 | 44.9 | 227 | 42.2 | 0.85 | 0.68 – 1.06 | 162 | 45.9 | 1.07 | 0.83 – 1.38 |
| AA | 109 | 8.8 | 40 | 7.4 | 0.70 | 0.47 – 1.04 | 37 | 10.5 | 1.16 | 0.77 – 1.77 |
| p-value for trend | 0.043 | 0.42 | ||||||||
| GA or AA vs. GG | 0.83 | 0.68 – 1.02 | 1.09 | 0.86 – 1.39 | ||||||
| AA vs. GG or GA | 0.75 | 0.51 – 1.10 | 1.12 | 0.75 – 1.67 | ||||||
|
| ||||||||||
| HPCX markers | ||||||||||
| B97 – 135 | 42 | 4.3 | 27 | 6.9 | 1.66 | 1.01 – 2.76 | 17 | 7.3 | 1.77 | 0.98 – 3.17 |
| DXS1205 – 188 | 44 | 4.5 | 31 | 7.9 | 1.84 | 1.14 – 2.99 | 11 | 4.9 | 1.12 | 0.56 – 2.21 |
| D33 – 248 | 168 | 17.3 | 62 | 16.3 | 0.91 | 0.66 – 1.26 | 28 | 12.1 | 0.65 | 0.42 – 0.99 |
†
Nr of cases and controls that were genotyped for RNASEL and HPCX vary by genetic marker
‡
ORs and 95% CI are adjusted for age. The reference category for ORs of each allele of HPCX microsatellite markers are other alleles in the same microsatellite marker